Grace Therapeutics, Inc.
GRCE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $2 | $0 |
| Gross Profit | $0 | $0 | -$2 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $568 | $955 | $1,634 | $2,194 |
| G&A Expenses | $0 | $2,133 | $0 | $1,509 |
| SG&A Expenses | $1,961 | $2,133 | $1,547 | $1,509 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $0 | $1 |
| Operating Expenses | $2,529 | $3,090 | $3,181 | $3,704 |
| Operating Income | -$2,529 | -$3,090 | -$3,183 | -$3,704 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,591 | -$272 | $2,801 | -$1,056 |
| Pre-Tax Income | -$938 | -$3,362 | -$382 | -$4,760 |
| Tax Expense | $0 | $0 | -$1,018 | -$605 |
| Net Income | -$938 | -$3,362 | $636 | -$4,155 |
| % Margin | – | – | – | – |
| EPS | -0.06 | -0.21 | 0.046 | -0.36 |
| % Growth | 71.4% | -552.6% | 112.9% | – |
| EPS Diluted | -0.06 | -0.21 | 0.046 | -0.36 |
| Weighted Avg Shares Out | 15,925 | 15,925 | 13,718 | 11,506 |
| Weighted Avg Shares Out Dil | 15,925 | 15,925 | 13,718 | 11,506 |
| Supplemental Information | – | – | – | – |
| Interest Income | $172 | $205 | $167 | $138 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $2 | $2 |
| EBITDA | -$938 | -$3,088 | -$380 | -$3,702 |
| % Margin | – | – | – | – |